Koers Mabvax Therapeutics Holdings Inc Nasdaq
Aandelen
US55414P5044
Biotechnologie & Medisch Onderzoek
Omzet 2016 | 148K 138K | Omzet 2017 | - | Marktkapitalisatie | 14,41 mln. 13,39 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2016 | -17 mln. -15,79 mln. | Nettowinst (verlies) 2017 | -19 mln. -17,65 mln. | EV/omzet 2016 | 147 x |
Nettoschuld 2016 | 470K 437K | Nettoschuld 2017 | 2,48 mln. 2,31 mln. | EV/omzet 2017 | - |
K/w-verhouding 2016 |
-0,93
x | K/w-verhouding 2017 |
-0,25
x | Werknemers | - |
Dividendrendement 2016 * |
-
| Dividendrendement 2017 |
-
| Vrij verhandelbaar | 92,02% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 08-07-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+38,61% | 12,63 mld. | |
+313,59% | 8,49 mld. |